3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Neuroendocrine Tumors
5
Meningioma
3
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoid Tumor
2
Prostatic Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Ganglioneuroma
1
Ganglioneuroblastoma
1
Disease
1
Carcinoma, Medullary
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Interventions
Fulvestrant
5
dalpiciclib
3
Letrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
exemestane
2
apatinib
2
Anastrozole
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liposomes
1
Irinotecan
1
Ga(III)-DOTATOC
1
Everolimus
1
Cell Separation
1
Capecitabine
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Cancer Metastatic
×
Ga(III)-DOTATOC
×
Clear all
NCT06611891
2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3
Recruiting
25 enrolled